The first 60 days: Ependymoma

Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.

• Newly diagnosed intracranial ependymoma, age one year and overCOG ACNS0121 (JCO 2019); NCI PDQ

  Maximal safe resection, second-look surgery for residual disease, then conformal or proton radiotherapy to the tumour bed (ACNS0121 approach); craniospinal irradiation only for disseminated disease.

  IMRT / IGRT (modern external beam)Proton therapyMRIACNS0121

These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.

• PathologistNamed in the standard of care for: Recurrent.
• RadiologistNamed in the standard of care for: Newly diagnosed intracranial ependymoma, age one year and over.
• SurgeonNamed in the standard of care for: Newly diagnosed intracranial ependymoma, age one year and over, Infants under one year or unresectable residual, Recurrent.
• Medical oncologistNamed in the standard of care for: Newly diagnosed intracranial ependymoma, age one year and over, Infants under one year or unresectable residual, Recurrent.
• Clinical oncologist (radiotherapy)Named in the standard of care for: Newly diagnosed intracranial ependymoma, age one year and over, Infants under one year or unresectable residual, Recurrent.
• Transplant and cell therapy teamNamed in the standard of care for: Infants under one year or unresectable residual.

A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.

Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.

1. 1.Infants under one year or unresectable residualSIOP Ependymoma II; NCI PDQ

   Chemotherapy (vincristine, carboplatin, cyclophosphamide, etoposide-based) to delay radiotherapy or facilitate second surgery, per SIOP Ependymoma II and COG protocols.

   VincristineCarboplatinCyclophosphamideEtoposide
2. 2.Recurrent

   Repeat resection and re-irradiation (focal or craniospinal) where feasible; no standard systemic therapy, so trial enrolment (including Pediatric MATCH-style molecular assignment) is recommended.

   NCI-COG Pediatric MATCH (APEC1621)Proton therapy

Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.

Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.

• NCI-COG Pediatric MATCH (APEC1621)Platform trial · active · NCT03155620Relapsed or refractory solid tumours, non-Hodgkin lymphomas and histiocytic disorders, age 1-21: tumour sequencing then assignment to one of a dozen single-agent targeted-therapy phase 2 arms
• A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With CancerPhase 1/2 · active · NCT06521567Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)

Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.

• Free in oncologyFree testing, helplines, rides and lodging, second opinions and trial travel help, with who is eligible.
• Financial helpManufacturer programmes, national schemes and charities by country and product.
• Second opinionExpert centres for this cancer in your country and how referral works.

• Ependymoma: the full pageEpendymomas grow from the cells lining the fluid spaces of the brain and spinal cord, mostly in children under five. Removing the whole tumour followed by focused radiotherapy controls most cases; molecular groups defined in 2021 behave differently, with posterior fossa group A relapsing often, and there is no approved drug.
• One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
• Treatment sequencingWhich treatment tends to follow which, line by line.
• NavigatorStandard of care for your stage, what you have tried, and trials near you.